Výsledky vyhledávání - "Masashi Nishimi"

Akademický článek

Frontline use of rituximab may prevent ADAMTS13 inhibitor boosting during caplacizumab treatment in patients with iTTP: post hoc analysis of a phase 2/3 study in Japan

Autor: Kazunori Imada, Yoshitaka Miyakawa, Satoshi Ichikawa, Hitoji Uchiyama, Yasunori Ueda, Yasuhiro Hashimoto, Masashi Nishimi, Masako Tsukamoto, Sayaka Tahara, Masanori Matsumoto

Publikováno v: Thrombosis Journal, Vol 22, Iss 1, Pp 1-8 (2024)

Abstract Background A recent Phase 2/3 study in Japanese patients showed that caplacizumab was effective in treating immune-mediated thrombotic thrombocytopenic purpura (iTTP), with a low rate of iTTP recurrence. ADAMTS13 activity is monitored weekly

Externí odkaz: https://doaj.org/article/871d701cd0654ce9b4f10eafb205124e

Zobrazit plný text záznamu

Akademický článek

Frontline use of rituximab may prevent ADAMTS13 inhibitor boosting during caplacizumab treatment in patients with iTTP: post hoc analysis of a phase 2/3 study in Japan.

Autor: Imada, Kazunori¹ (AUTHOR), Miyakawa, Yoshitaka² (AUTHOR), Ichikawa, Satoshi³ (AUTHOR), Uchiyama, Hitoji⁴ (AUTHOR), Ueda, Yasunori⁵ (AUTHOR), Hashimoto, Yasuhiro⁶ (AUTHOR), Nishimi, Masashi⁶ (AUTHOR), Tsukamoto, Masako⁶ (AUTHOR), Tahara, Sayaka⁶ (AUTHOR), Matsumoto, Masanori⁷ (AUTHOR) mmatsumo@naramed-u.ac.jp

Publikováno v: Thrombosis Journal. 8/2/2024, Vol. 22 Issue 1, p1-8. 8p.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Periodical

Reports Outline CD20 Monoclonal Antibodies Study Results from Department of Hematology (Frontline use of rituximab may prevent ADAMTS13 inhibitor boosting during caplacizumab treatment in patients with iTTP: post hoc analysis of a phase 2/3...).

Publikováno v: Immunotherapy Weekly; 8/22/2024, p1632-1632, 1p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání